I am currently a student working on obtaining a Master's degree in Biomedical Sciences, and I have completed a Bachelor's in Biotechnology. While my background in biotechnology gives me a great perspective into high growth companies, I prefer to focus on equities that are undervalued no matter what sector they fall under. I focus on fundamentals such as Price/Free-Cash-Flow and Price/Book to determine the ideal value of the company and I research management and their prior experience to determine whether to discount or add a premium to the ideal value. I do not use technical data to determine what makes a good investment. Rather, I use it to determine when is the best time to open or close a position in a company that I have determined to be undervalued or overvalued.
Netherlands based non-professional stocktrader with a private portfolio; good at stockpicking; not good at options. I prefer companies with a good ROI, ROE, PEG-ratio, good and inspiring management, a durable competative advantage. BUY AND ACCUMULATE (B&A) is my approach. I'm in the market for the company's profit, not the stockprice in the first place.
I am presently a PhD Candidate in marketing at the Schulich School of Business in Toronto, Canada (is.gd/weO3eP). I've been investing since 2005 and am an avid reader of (and occasional commenter on) Seeking Alpha. I think Seeking Alpha and its contributors offer great ideas on and insights into both how and where to invest.
From a research perspective, I am Interested in how investors - on forums such as Seeking Alpha - work together to make sense of and understand (and give sense about) the uncertain and ambiguous movements and signals of the market.
If you would be willing to help out with this research, I would be appreciative of your assistance. I'm interested in interviewing contributors (authors and commenters, such as yourself) to the site about how and why they use, contribute to and benefit from Seeking Alpha (e.g. What role does SA play in your investing? What contributions do you benefit from the most? What goes into making a contribution on the site?). Any interview would occur at your convenience (over Skype or phone) and would last approximately 60-90 minutes. Your responses will be instrumental in the development of research that will be targeted towards a top-tier academic journal (and will help me out with my dissertation!). In order to maintain anonymity, unless you specifically indicate otherwise, any direct quotes reported from your interview will be attributed to a pseudonym.
If you're interested in assisting with this research (or just finding out more about it), please send me a note here or at firstname.lastname@example.org. Thank you for your consideration!
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
I have written 2 dutch books on value investing: "Aandelen selecteren als waardebelegger" and "Beleggen in bull- en bearmarkten". See bol.com (search for the titles).
As a mathematician (Ph.D.) I am most interested in investment strategies with statistically favorable returns. In particular I invest in net-nets (20-30% average annual returns). I find companies with low Enterprise Value/Earnings before Tax and Interest (EV/EBIT) and strong balance sheets (20% average annual returns) also very interesting. Since such stocks are rare I invest globally.
Click "Learn more" below to see my exclusive research description on net-nets and low EV/EBIT stocks.
I am a private investor with a broad portfolio diversified across sector and size. Most of my writing, and much of the speculative portion of my portfolio, focuses on small and mid-cap companies in the healthcare and biotechnology sector. This sector provides the opportunity for outsize rewards, though one must be willing to accept significant risk. My background has exposure to healthcare investing and involvement with operating companies, which I believe provides me with a unique perspective. Currently I am an Associate for Finance and Business development at a clinical stage oncology company called Oncoceutics. Previously I was an Analyst at Osage University Partners, a venture capital firm focused on investing in companies developing technologies licensed from universities across a broad spectrum of opportunities including life sciences, information technology, cleantech, hardware and advanced materials. Prior to that, I worked for a grant program directed at life science technology commercialization at the University City Science Center. I also have worked at BlackRock Asset Management in an operations role with the money market and municipal bond fund groups.
I have a B.S. in Finance and Entrepreneurship with a minor in Biological Sciences from Drexel University, and hold the Chartered Financial Analyst (CFA) designation.